Mabion S.A. (WSE:MAB)
8.26
+0.01 (0.12%)
Jan 28, 2026, 5:00 PM CET
Mabion Revenue
Mabion had revenue of 4.08M PLN in the quarter ending September 30, 2025, with 691.47% growth. This brings the company's revenue in the last twelve months to 14.81M, down -86.63% year-over-year. In the year 2024, Mabion had annual revenue of 69.02M, down -54.50%.
Revenue (ttm)
14.81M
Revenue Growth
-86.63%
P/S Ratio
9.00
Revenue / Employee
70.53K
Employees
213
Market Cap
133.34M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 69.02M | -82.66M | -54.50% |
| Dec 31, 2023 | 151.68M | -12.30M | -7.50% |
| Dec 31, 2022 | 163.98M | 127.92M | 354.72% |
| Dec 31, 2021 | 36.06M | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BIOTON | 295.81M |
| Ryvu Therapeutics | 90.41M |
| Synthaverse | 71.76M |
| Captor Therapeutics Spolka Akcyjna | 7.57M |
| Molecure | 5.86M |
| Urteste | 1.80M |
| Pharmena | 1.27M |
| Poltreg | 250.00K |